M&T Bank’s Summit Therapeutics SMMT Stock Holding History

M&T Bank’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-25,000	Closed	-$74K	–	1651
2020 Q2	$74K	Buy	+25,000	New	+$86.2K	﹤0.01%	1472

Other funds holding SMMT

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BBR Partners New York $1.79B AUM 16.83% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

M&T Bank's SMMT Position: Q3 2020 in Review

M&T Bank sold out of Summit Therapeutics (SMMT) in Q3 2020, closing a stake of 25,000 shares — an estimated $74K sold.

M&T Bank first reported a position in SMMT in Q2 2020 and held it in 1 quarter. The position peaked at $74K in Q2 2020. 19 funds tracked by Wall St. Rank hold SMMT as of Q3 2020.

M&T Bank reported no remaining Summit Therapeutics position as of Q3 2020 after selling out during the quarter.
M&T Bank sold 25,000 Summit Therapeutics shares in Q3 2020, an estimated $74K.
M&T Bank first reported a position in Summit Therapeutics in Q2 2020 and held it in 1 quarter.
M&T Bank's Summit Therapeutics position peaked at $74K in Q2 2020.
19 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2020.

Based on M&T Bank's 13F filing for Q3 2020, filed 6 Nov 2020.